Quarterly report pursuant to Section 13 or 15(d)

Collaborations, Licensing Agreements and Other Agreements - Additional Information (Details)

v3.24.3
Collaborations, Licensing Agreements and Other Agreements - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Mar. 31, 2023
May 31, 2020
Sep. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Jan. 31, 2024
Dec. 31, 2023
Aug. 31, 2023
Oct. 07, 2022
Dec. 31, 2021
Collaborations, Licensing Agreements And Other Agreements [Line Items]                        
Research and development expense     $ 26,290,000   $ 13,787,000 $ 71,671,000 $ 38,019,000          
Upfront payment                 $ 1,100,000      
License Agreement                        
Collaborations, Licensing Agreements And Other Agreements [Line Items]                        
Obligation to be paid     2,000,000     $ 2,000,000            
Payment term           3 years            
Payment commencement date           2018-08            
License maintenance fee   $ 33,000       $ 10,000            
Total milestone payments           21,000,000            
Amounts due to agreement     0     0            
Sponsored Research Agreements                        
Collaborations, Licensing Agreements And Other Agreements [Line Items]                        
Obligation to be paid     12,560,000     12,560,000            
Master Translational Research Services Agreement                        
Collaborations, Licensing Agreements And Other Agreements [Line Items]                        
Research and development expense     888,000   $ 668,000 2,408,000 $ 2,873,000          
Remaining research and development expense to be incurred           643,000            
Oxford Biomedica                        
Collaborations, Licensing Agreements And Other Agreements [Line Items]                        
Obligation to be paid     5,000,000     5,000,000           $ 4,000,000
Research and development expense           1,100,000            
Upfront payment                   $ 500,000    
Expenses           4,800,000            
Nanjing IASO Biotherapeutics Co., Ltd. [Member]                        
Collaborations, Licensing Agreements And Other Agreements [Line Items]                        
Total milestone payments $ 1,000,000     $ 1,500,000                
Upfront payment     $ 162,000,000     162,000,000         $ 2,500,000  
Autolus Holdings [Member]                        
Collaborations, Licensing Agreements And Other Agreements [Line Items]                        
Upfront payment $ 1,200,000             $ 100,000        
Autolus Holdings [Member] | Maximum [Member]                        
Collaborations, Licensing Agreements And Other Agreements [Line Items]                        
Total milestone payments           15,000,000            
Autolus Holdings [Member] | Maximum [Member] | License and Service [Member]                        
Collaborations, Licensing Agreements And Other Agreements [Line Items]                        
Total milestone payments           $ 12,000,000